Experience with prolonged high dose administration of promethazine-HC1 (Phenergan-HCI) to pregnant women has suggested that it may ameliorate some of the effects of erythroblastosis fetalis in Rh-incompatible sensitized gestations (2, 8) . Its beneficial effects in possibly reducing the severity of hyperbilirubinemia and anemia have been attributed entirely to the ability of the drug to suppress macrophage activity in the fetal reticuloendothelial system, thereby reducing the rate of fetal erythrocyte lysis (8) .
Promethazine is a potent ,inhibitor of several immune mechanisms, as had been reported previously by others (7) and as we have observed in studies from our own institution in infants whose mothers had been so treated (16, 17) . Nevertheless, the clinical course of several of these neonates with Rh erythroblastosis whose mothers had been treated with promethazine at 75-175 mg/day for 2-14 weeks suggested that supression of hemolysis would not alone account for the observed effect of therapy in preventing the expected rise in serum bilirubin concentrations (16) . The continuation of severe hemolysis without a comparable increase in serum bilirubin concentration suggested the possibility that promethazine-HCI enhanced bilirubin disposal mechanisms of the liver in a manner similar to that of phenobarbital, benzpyrene, dichlordiphenyltrichlormethylmethane, and other microsomal enzymeinducing agents (3, 5) .
As an initial approach to this question, hepatic bilirubin uptake, conjugation, and excretion were studied in adult rats which had been treated with promethazine-HC1.
MATERIALS AND METHODS
Sprague-Dawley female adults rats weighing 235-260 g were obtained from Marland Breeding Farms, Wayne, N. J. The animals were maintained in a stable environment and fed Purina rat chow. Pure promethazine-HCI (a gift of Wyeth Laboratories Inc.) was prepared in normal saline (250 mg/100 ml) and administered in doses of 25 mg/kg/24 hr sc once a day for 2 1 days. Control animals received the same volume of normal saline. Animals were weighed weekly. In one group of animals (eight treated, six control) hepatic bilirubin UDP-glucoronyl transferase activity was measured according to a method previously described (6) .
The remaining animals underwent cannulation of the trachea, external jugular vein, and common bile duct with pentobarbital anesthesia. Body temperature was maintained with the use of a thermostatically controlled heating cabinet and an infrared lamp; rectal temperatures were measured to insure maintenance of temperature between 99.0 and 100.0" F. Hepatic uptake and excretion of bilirubin were studied and calculated as previously described (6), with two 30-min periods of infusion of normal saline followed by six 15-min periods of infusion of bilirubin (100 mg/100 ml buffered saline, pH 7.8). Bile was collected on ice in the dark during each study period. Blood was collected terminally. Livers were removed, blotted, and weighed immediately after the rats were killed at the termination of the last period. Total liver protein was measured according to the method of Lowry (10) .
Results are expressed as the mean value rt 1 SE. The two tailed t-test was used for determination of statistically significant differences between groups at a significance level of P < 0.05 (18) .
RESULTS
The results are summarized in Table 1 .
E N D O G E N O U S BILIRUBIN EXCRETION
Bile flow and bile bilirubin concentrations during the 60-min period of saline infusion, before bilirubin infusion, is designated endogenous bile flow and endogenous bile bilirubin concentration, respectively. The product of these two parameters yields the endogenous bilirubin excretion which, in the steady state of these animals, represents the load of bilirubin presented to liver and, therefore, a measure of bilirubin synthesis. Mean endogenous bilirubin excretion in the control rats was 0.361 0.03 pg/lOO g body w/min while it was more than double (0.782 + 0.12) in the treated animals. This difference is significant ( P < 0.01).
C U M U L A T I V E H E P A T I C U P T A K E
Cumulative hepatic bilirubin uptake is a measure of the maximal net rate of movement of unconjugated bilirubin from Table 1 . Effects of Promethazine-HCl on bilirubin metabolism in rati n Control n Promethazine-HCI P Cumulative hepatic uptake (lrg/ 100 g/min) Glucuronyl transferase (pg bilirubin conjugatedlg I1ver/40 min) Endogenous bilirubin (pg/100 g/min) Bile bilirubin (ng/ 100 ml) Bile flow 100 g/min) Hepatic bilirubin excretion (pg/100 g/min) Total bilirubin excreted (mg) Serum bilirubin Indirect (mg/ 100 ml) Direct (mg/100 ml) Liver bilirubin Indirect (mg/ I00 ml) Direct (mg/ 100 ml) Liver protein concentration (mg/g liver) Total liver protein (mg/ 100 g body wt) Liver weight (g/ 100 g body wt) Body weight at start of injections (g) Body weight at end of 21 days of injections (g) ' All values represent the mean i I SE plasma into the liver and was calculated as previously described (6) . Cumulative hepatic uptake of bilirubin was 84.5 + 7.6 pg/ 100 g/min in control rats. The promethazine-HCI-treated group had a significant increase to 110.0 * 4.3 ( P < 0.01).
BILIRUBIN U D P -G L U C U R O N Y L T R A N S F E R A S E ACTIVITY
The control group had a mean enzyme activity estimated in vitro of 1,330 86 pg bilirubin conjugatedlg liver140 min whereas the promethazine-HCI-treated group had a significant increase to 1,713 * 61 ( P < 0.01).
M A X I M A L BILE BILIRUBIN C O N C E N T R A T I O N
Maximal bile bilirubin concentration was calculated for each animal as the mean of the three periods identified as having maximal hepatic bilirubin excretion. The mean maximal bilirubin concentration achieved in bile was not significantly different between control and promethazine-HCI groups: 604.5 A 62 and 668.7 * 36 mg/100 ml, respectively ( P > 0.20).
BILE FLOW
Bile flow as calculated for each animal was a mean of the same three periods used for mean maximal hepatic bilirubin excretion.
The control group had a mean bile flow of 7.8 * 0.89 pg/100 g body wt/min and the promethazine-HCI group, 9.5 i 0.63. This difference is not significant ( P > 0.10).
M A X I M A L H E P A T I C BILIRUBIN EXCRETION
Maximal hepatic excretion of bilirubin was calculated for each animal as a mean of the three highest values of the six bilirubin infusion periods. This represents the maximal rate at which the liver can transfer conjugated bilirubin out of the liver. The mean maximal hepatic bilirubin excretion of 63.5 + 2.7 pg/100 g/min in the promethazine-HCI group was significantly greater than the 47.2 * 4.9 of the control group ( P < 0.02).
T O T A L BILIRUBIN EXCRETED
The control group excreted 19.6 * 2.1 mg bilirubin during the 90-min bilirubin infusion period whereas the promethazine-HCI group excreted a significantly greater amount, 24.8 i 1.4 mg (P < 0.05).
S E R U M A N D LIVER BILIRUBIN C O N C E N T R A T I O N S
At the completion of each infusion study, bilirubin concentrations were determined in liver and serum. Control rats had a mean indirect-reacting bilirubin concentration in serum of 15.6 * 2.6 mg/ 100 ml and a mean direct-reacting bilirubin in serum of 1.6 + 0.7. Promethazine-HCI-treated rats had 13.1 i 1.6 and 2.0 * l .O, respectively. The differences were not significant for either direct or indirect-reacting bilirubin concentrations ( P > 0.20).
The mean concentration of indirect-reacting bilirubin in liver at the completion of the study in control animals was 17.1 * 2.3 mg/ 100 ml and the mean direct-reacting bilirubin was 7.7 * 1 .O.
Promethazine-HCI-treated rats had 15.2 2.3 and 9.4 i 2.4, respectively. The differences between control and treated animals are not significant ( P > 0.20).
T O T A L BODY W E I G H T BEFORE A N D AFTER T R E A T M E N T
The mean total body weight at start of treatment was similar in both groups: 246.7 =t 10.1 g for the control group and 247.9 * 10.4
for the promethazine-HCI-treated rats. After the 21-day treatment the total body weight was higher in the control group (286.6 * 14.6) g compared with promethazine-HCI-treated rats (277.7 * 16.9) but the difference is not significant ( P > 0.10).
LIVER W E I G H T
The mean liver weight for the control group was 3.46 0.04 g/100 g body wt. The promethazine-HCI-treated rats had a significantly greater liver weight of 3.83 * 0.07 ( P < 0.001). 
DISCUSSION
Three weeks of promethazine-HCI adminisration produced a significant enhancement of both bilirubin metabolism and transport in the rat. These effects of promethazine-HCI are similar to those described for phenobarbital which has been shown to increase bilirubin conjugation (3, 5) excretion (I, 15), and possibly uptake (9, 13, 14) . Promethazine-HCI also increased liver weight and total liver protein as has been observed previously following prolonged administration of most enzyme inducers. Furthermore, the significantly higher endogenous bilirubin excretion in the promethazine-HCI-treated rats strongly suggests that bilirubin production is also increased in these animals, an observation not previously noted with phenobarbital.
The increase in hepatic transport and conjugation of bilirubin strongly suggests that promethazine is a potent stimulator or inducer of enzyme and protein synthesis, as has been noted for a number of other drugs of the antihistamine group (4). This observation increases the likelihood that a significant portion of the clinical effectiveness of promethazine resides in its ability to enhance bilirubin disposal. The suggested increase in bilirubin production noted in the promethazine-treated rats, although significant, is of relatively small degree compared with enhancement of other transport parameters and is heavily compensated for by increased excretion.
The precise mechanism by which any of these drugs increase hepatic uptake and excretion is unknown. It has been suggested that uptake is enhanced by increased synthesis of the cytoplasmic bilirubin binding protein, ligandin ("Y"), and that excretion is enhanced by increased bile salt-independent bile flow, and/or by increased bile salt synthesis and pool size (9, (12) (13) (14) .
In some of the treated human infants the effect on bilirubin disposal mechanisms appeared to be greater than the role of the drug in reducing hemolysis. The question is raised, therefore, of whether promethazine has any advantage over phenobarbital, which has already been shown to reduce the number of exchange transfusions required in newborns with rhesus hemolyiic disease (11) . If the long term immunosupressive effects produced by promethazine-HCI prove to have serious consequences later in life, as has been suggested by some of the early studies from this department, then the clinical usefulness of promethazine would be in much doubt (16) . Although the number of women sensitized to Rh antigen has been reduced markedly in recent years, comparative study of the effects of promethazine and phenobarbital in potential Rh erythroblastosis during pregnancy, neonatal, and infancy periods would clarify some of these issues.
S U M M A R Y
A significant increase in hepatic bilirubin uptake, hepatic conjugation, and maximal hepatic excretion was observed in adult rats after promethazine administration for 21 days. Total liver weight and hepatic protein were also increased significantly by the treatment.
The study suggests that promethazine is a potent stimulator or inducer of enzyme and protein synthesis and the benefit of promethazine in the treatment of R h erythroblastosis may relate to enhancement of bilirubin disposal mechanisms.
